Free Trial

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS)

Arbutus Biopharma logo with Medical background

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 195,843 shares of the biopharmaceutical company's stock, valued at approximately $754,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.10% of Arbutus Biopharma as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ABUS. Rubric Capital Management LP bought a new position in Arbutus Biopharma in the 2nd quarter worth about $5,195,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Arbutus Biopharma by 218.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,212,246 shares of the biopharmaceutical company's stock valued at $4,667,000 after purchasing an additional 831,663 shares during the period. Susquehanna Fundamental Investments LLC grew its stake in Arbutus Biopharma by 102.2% in the second quarter. Susquehanna Fundamental Investments LLC now owns 208,152 shares of the biopharmaceutical company's stock worth $643,000 after purchasing an additional 105,228 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Arbutus Biopharma by 21.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 493,729 shares of the biopharmaceutical company's stock worth $1,526,000 after purchasing an additional 86,104 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Arbutus Biopharma during the 3rd quarter valued at $204,000. Hedge funds and other institutional investors own 43.79% of the company's stock.

Arbutus Biopharma Price Performance

ABUS stock remained flat at $3.21 during trading on Friday. The company had a trading volume of 2,993,658 shares, compared to its average volume of 1,090,724. The company has a market capitalization of $608.27 million, a P/E ratio of -7.46 and a beta of 1.84. The company's 50 day moving average price is $3.72 and its 200 day moving average price is $3.70. Arbutus Biopharma Co. has a 12 month low of $2.21 and a 12 month high of $4.72.

Wall Street Analyst Weigh In

ABUS has been the topic of a number of recent research reports. Jefferies Financial Group increased their price target on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. JMP Securities increased their target price on shares of Arbutus Biopharma to $5.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Monday, November 18th. Finally, Chardan Capital reiterated a "buy" rating and set a $5.00 price objective (up from $4.50) on shares of Arbutus Biopharma in a research note on Wednesday, November 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Arbutus Biopharma currently has an average rating of "Moderate Buy" and an average price target of $5.50.

View Our Latest Stock Report on Arbutus Biopharma

Arbutus Biopharma Profile

(Free Report)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

Further Reading

Institutional Ownership by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Should you invest $1,000 in Arbutus Biopharma right now?

Before you consider Arbutus Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.

While Arbutus Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines